PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.43%
Cash & equivalents declining -9.43% while Medical - Pharmaceuticals shows 0.00% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-9.43%
Below half the Medical - Pharmaceuticals median of 0.00% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
No Data
No Data available this quarter, please select a different quarter.
5.76%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-3.11%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-1.65%
Below half the Medical - Pharmaceuticals median of 0.00%. Jim Chanos would question if the company faces working capital strain.
6.91%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
-1.51%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-1.51%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.27%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
5.12%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
1.70%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-0.57%
Payables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-9.12%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
86.20%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
85.08%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
0.29%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
1.58%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects potential working capital strain.
-14.33%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.70%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-7.84%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
0.11%
50-75% of Medical - Pharmaceuticals median of 0.18%. Mohnish Pabrai notes a relatively conservative approach to liabilities.
No Data
No Data available this quarter, please select a different quarter.
7.32%
≥ 1.5x Medical - Pharmaceuticals median of 1.71%. Joel Greenblatt sees stronger retained profit growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-33.33%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
4.85%
≥ 1.5x Medical - Pharmaceuticals median of 0.96%. Joel Greenblatt sees stronger equity growth vs. peers.
1.70%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
-12.38%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
7.11%
Above 1.5x Medical - Pharmaceuticals median 1.42%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.